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eterminants of
yocardial Recovery in Myocarditis
as the Time Come
or Molecular Fingerprinting?*
ouglas L. Mann, MD, FACC
ouston, Texas
he clinical presentation of viral myocarditis is quite variable,
anging from asymptomatic left ventricular (LV) dysfunction
o fulminant heart failure culminating in death. Although
ongitudinal follow-up studies of patients with suspected viral
yocarditis suggest that spontaneous recovery of myocardial
unction occurs in approximately 40% to 60% of patients (1,2),
he clinical prognosis is far less sanguine for those patients in
hom myocardial recovery is limited or absent (2,3). Indeed,
or patients who developed persistent LV dysfunction in the
yocarditis Treatment Trial the mortality was 60% during the
ollow-up period (mean duration 18 months) (2). Thus, the
bility to prospectively identify subsets of patients in whom
yocardial recovery is limited, and (by extension) patients
hose clinical prognosis is less favorable, would appear to be of
ignificant clinical importance, insofar as the ability to identify
hese patients would allow clinicians to design appropriate
reatment strategies earlier in the course of the disease, before
he transition to symptomatic heart failure occurs.
See page 1036
In this issue of the Journal, Sheppard et al. (4) report on
series of patients enrolled in a gene expression substudy of
he Intervention in Myocarditis and Acute Cardiomyopathy
IMAC) trial (5). These investigators examined myocardial
xpression levels of messenger ribonucleic acid (mRNA) for
portfolio of genes that have been linked to cardiac myocyte
poptosis, including tumor necrosis factor (TNF), tumor
ecrosis factor receptor-1 (TNFR1), Fas, Fas ligand
FasL), and FLICE (Fas-associated death domain-like
nterleukin-1 beta-converting enzyme) in relation to recov-
ry of LV function at six months (n  20 patients). The
uthors found that subjects with the highest tertile of Fas
xpression had minimal improvement in LV function at six
onths. In contrast, patients who had intermediate or lower
ertiles of Fas mRNA expression had spontaneous improve-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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eart Institute, Houston, Texas. This work was supported by research funds from thei
ational Institutes of Health (P50 HL-O6H and RO1 HL58081-01, RO1
L61543-01, HL-42250-10/10).ent in their LV function. A similar inverse relationship
as observed for the expression levels of TNFR1 and LV
unction. In contrast, analysis of mRNA levels for TNF,
asL, and FLICE by tertiles did not predict myocardial
ecovery. Given that the cytoplasmic tails of both TNFR1
nd Fas contain so-called “death-domains” that serve as
ocking stations for activation of pro-apoptotic caspases,
he authors suggest that ongoing apoptosis may limit
yocardial recovery in viral myocarditis. Before discussing
he significance of these findings, it is useful to digress for a
oment and discuss what is known about our ability to
redict myocardial recovery in viral myocarditis.
YOCARDIAL RECOVERY IN VIRAL MYOCARDITIS
lthough a number of studies have reported prognostic
actors that predict clinical recovery for patients with myo-
arditis, far less is know with respect to predicting myocar-
ial recovery. As shown in Table 1, clinical studies have
emonstrated relatively few clinical or biological markers
hat predict myocardial recovery. Bossone et al. (6) have
hown that neither New York Heart Association (NYHA)
unctional class nor ejection fraction (EF) at presentation
redicted LV recovery, whereas a small left atrial and LV
ize were both predictive of myocardial recovery (n  15
atients). Scintigraphic evidence of increased uptake of
nti-myosin antibodies (presumably reflecting increased
yocyte necrosis) was also shown to weakly predict short-
erm recovery of LV function in patients with suspected
yocarditis (n  50 patients) (7). However, in a different
tudy neither creatinine kinase, cardiac troponin I, nor
yoglobin levels predicted LV recovery (n  22 patients),
uggesting that factors other than myocyte necrosis contrib-
te to the acute LV dysfunction observed in myocarditis (8).
n the Myocarditis Treatment Trial (n  111 patients) the
se of immunological biomarkers (cardiac and general
mmunoglobulin G titers, helper T-cell count, natural killer
ells) and total white blood cell count was not predictive of
V myocardial recovery (2,9). Moreover, histological anal-
ses of myocardial biopsy samples have yielded mixed results
n terms of predicting LV recovery. That is, neither the
resence of white cell infiltrates (2) nor the presence of
yofibrillar degeneration predicted LV recovery (3),
hereas the absence of Azan-Mallory staining of cardiac
yocytes (a marker of cellular edema and/or myocytolysis)
redicted LV recovery in biopsy-proven myocarditis (n 
0 patients) (10). Finally, the presence of enteroviral minus
trand ribonucleic acid (indicative of actively replicating
irus) on a myocardial biopsy has been shown to predict
rogression to a dilated cardiomyopathic phenotype (n 45
atients) (3,11). Thus, save for a few single-center studies
onducted on relatively small numbers of patients, there are
irtually no reliable clinical tools for predicting LV recovery
n the setting of viral myocarditis.
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Editorial Comment September 20, 2005:1043–4an expression levels of mRNA levels for one or more
enes be used as a method for predicting LV recovery in
iral myocarditis? As noted at the outset, the study by
heppard et al. (4) in this issue of the Journal suggests that
ubjects with the highest tertile of Fas and TNFR1 expres-
ion had minimal improvement in LV function at six
onths. Given that both TNFR1 and Fas belong to the
NF receptor superfamily of receptors that play a critical
ole in the induction of apoptosis, as well as T-cell and
atural killer cell-mediated toxicity (12), and that circulat-
ng levels of soluble Fas (the circulating “shed” form of the
as receptor) and soluble Fas ligand predict adverse patient
utcomes in myocarditis (13), the results of the study by
heppard et al. (4) make sense from a biological point of
iew. That is, ongoing Fas and/or TNFR1-induced
poptosis and progressive myocyte loss would be expected to
ttenuate or prevent the spontaneous LV recovery that
ccurs in myocarditis. Unfortunately, there was insufficient
issue to examine the presence or absence of cardiac myocyte
poptosis in relation to mRNA levels for that Fas and
NFR1 in the study by Sheppard et al. (4). Thus, it is
nclear whether the elevated levels of mRNA levels of Fas
nd TNFR1 represent a mechanism or a marker for persis-
ent LV dysfunction. Nonetheless, this provocative study
aises the broader question of whether it might be possible
o identify genetic profiles or “molecular fingerprints” in
yocardial biopsy samples that predict worsening LV func-
ion and untoward clinical outcomes in patients with myo-
arditis. Apart from the invaluable mechanistic information
hese types of investigations would provide, studies of this
ature would also be vitally important in terms of designing
linical trials for novel antiviral therapies, knowing when to
emove LV assist devices used as a “bridge” to recover
emodynamically unstable patients, as well as implementing
ppropriate supportive therapy for patients recovering from
able 1. Determinants of Myocardial Recovery in Myocarditis
YHA functional class at
presentation
Independent of LV recovery (6)
-D echocardiography
EF at presentation Independent of LV recovery (6)
Small LA size Predicts LV recovery (6)
Small LV dimensions Predicts LV recovery (6)
erological biomarkers
Troponin I Independent of LV recovery (8)
Creatinine kinase Independent of LV recovery (8)
Myoglobin Independent of LV recovery (8)
WBCs Independent of LV recovery (2)
Immunological markers Independent of LV recovery (2)
istologic markers
Inflammation Independent of LV recovery (9)
Myofibrillar degeneration Independent of LV recovery (3)
Poor Azan-Mallory staining Predicts LV recovery (10)
olecular markers
Enteroviral minus-strand RNA Progression to DCM (3,11)
CM  dilated cardiomyopathy; EF  ejection fraction; LA  left atrial; LV  left
entricular; NYHANew York Heart Association; RNA ribonucleic acid; WBCs
hite blood cells; 2-D  two-dimensional.yocarditis. Although this represents an ambitious chal-
1enge to the field, and would likely require data collection
rom multiple centers, the recent striking advances in gene
xpression profiling and bioinformatics now make it possi-
le to ask and answer this question. And indeed, our
olleagues in oncology have already begun to use molecular
ngerprinting for developing new therapies for treating
atients with breast and lung cancers (14), as well as
ymphomas (15). Although the results of the study by
heppard et al. (4) should be viewed as provisional because
f the small numbers of selected patients, their findings do
uggest that the advent of molecular fingerprinting could
ead to new targets and treatments for patients with viral
yocarditis.
cknowledgment
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